PTCT
PTC Therapeutics, Inc.
PTCT lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
PTCT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Strong |
PTCT's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
PTCT PE Valuation
PTCT has no meaningful PE right now: it lost money over the past year.
PTCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for PTCT, with profitability improving. However, they disagree widely on these estimates.
PTCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.88 | — |
| Q3 2026 | -$1.36 | -116% |
| Q2 2026 | -$0.54 | -108% |
| Q1 2026 | -$2.29 | -135% |
| Q4 2025 | $7.78 | +$12.51 |
| Q3 2025 | $8.56 | +$14.51 |
| Q2 2025 | $6.97 | +$13.29 |
| Q1 2025 | $6.51 | +$14.20 |
| Q4 2024 | -$4.73 | +$3.64 |
PTCT has swung to a loss: it lost $1.36 per share over the past year, after a profit the year before.
PTCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $357.8M | +70% |
| Q2 2026 | $360.5M | +102% |
| Q1 2026 | $272.6M | -77% |
| Q4 2025 | $164.7M | -23% |
| Q3 2025 | $211M | +7.2% |
| Q2 2025 | $178.9M | -4.2% |
| Q1 2025 | $1.2B | +460% |
| Q4 2024 | $213.2M | -31% |
PTCT's revenue is recovering but still below its 2025 peak: $358M last quarter, up 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | +5.6 points |
| Q2 2026 | 41% | +61 points |
| Q1 2026 | 17% | -66 points |
| Q4 2025 | -43% | +33 points |
| Q3 2025 | 1.4% | +29 points |
| Q2 2025 | -20% | +2 points |
| Q1 2025 | 83% | +104 points |
| Q4 2024 | -76% | -78 points |
PTCT's operating margin was 7% last quarter, up 5.6 points from the same quarter a year ago.
PTCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28M | +$41.8M |
| Q2 2026 | $126.9M | +$186.6M |
| Q1 2026 | -$60.2M | -107% |
| Q4 2025 | -$36.6M | -$2.9M |
| Q3 2025 | -$69.7M | +$7.8M |
| Q2 2025 | -$59.7M | +$4.4M |
| Q1 2025 | $868.4M | +1320% |
| Q4 2024 | -$33.8M | +$72.1M |
PTCT has burned cash in almost every quarter: $2M over the past year, down 100% from the year before.
PTCT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -2.5x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.6x | Net Cash |
| Q3 2024 | -15.8x | Net Cash |
| Q2 2024 | -51.7x | Net Cash |
PTCT's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
PTCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 24.9 | Neutral |
PTCT's weekly RSI is 44 (neutral) and its Stochastic is 25 (neutral).
PTCT PE vs Healthcare Sector
| Metric | PTCT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PTCT has no meaningful PE right now: it lost money over the past year.
PTCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.4 | 1.5% above |
| 20 week MA | $68.8 | 7.9% below |
| 50 week MA | $70.9 | 11% below |
| 100 week MA | $62.3 | 1.7% above |
| 200 week MA | $49.1 | 29% above |
PTCT's trend is mixed: it's above three of its five weekly moving averages, and 29% above its 200-week average.
PTCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.8 | $65.1 | +33% |
| 2021 | $65.1 | $41.9 | -36% |
| 2022 | $41.9 | $36.5 | -13% |
| 2023 | $36.5 | $27.6 | -24% |
| 2024 | $27.6 | $45.2 | +64% |
| 2025 | $45.2 | $78.6 | +74% |
| 2026 YTD | $78.6 | $63.4 | -19% |
PTCT has finished lower in three of the last six years. It's down 19% so far in 2026.